UK reg­u­la­tors cau­tion against switch­ing be­tween com­mon AD­HD meds

UK reg­u­la­tors have a mes­sage for AD­HD pa­tients and their providers: Take cau­tion when switch­ing be­tween long-act­ing forms of com­mon meds such as No­var­tis’ block­buster Ri­tal­in LA and Janssen’s Con­cer­ta XL.

The coun­try’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency (MHRA) is­sued a warn­ing on Mon­day about chang­ing long-act­ing for­mu­la­tions of methylphenidate, the ac­tive in­gre­di­ent in Ri­tal­in, Con­cer­ta and a host of oth­er drugs used to treat AD­HD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER